newsfilter
← Latest News
Business Wire·

DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Positive Phase 2 Interim Data Evaluating DM199 in Preeclampsia Showed Statistically Significant Reductions in Blood Pressure and Pulsatility Index as Well as No Placental Transfer $30 Million Private Placement